Senolytic CAR T cells

This is the most mechanically interesting senolytic approach in existence and it has never been given to a person for this purpose.

Small-molecule senolytics work by tipping already-stressed senescent cells over the edge into apoptosis, which means they are only as selective as the survival pathway they block. The CAR T approach inverts the problem. Instead of finding a drug that senescent cells cannot survive, find a protein that sits on their surface and build an immune cell that hunts it.

The protein is uPAR, the urokinase-type plasminogen activator receptor, identified in 2020 as broadly induced on the surface of senescent cells across several senescence programmes. T cells carrying a chimeric antigen receptor against uPAR cleared senescent cells in culture and in mice, extended survival in a mouse lung cancer model treated with a senescence-inducing drug pair, and restored tissue architecture in mice with chemically induced and diet-induced liver fibrosis. The 2020 Nature paper carries a published Author Correction from 2024.

A 2024 follow-up in Nature Aging reported something structurally important: a single administration in mice produced long-lasting benefit, improving exercise capacity in normally ageing animals and metabolic measures such as glucose tolerance in aged and high-fat-diet mice. If that holds, a cell therapy that persists would sidestep the repeat-dosing problem that every small-molecule senolytic has.

All of that is mice. CAR T therapy in people is not a gentle intervention: the approved products in blood cancer require lymphodepleting chemotherapy first and carry boxed warnings for cytokine release syndrome, neurologic toxicity, and since 2024 for secondary T cell malignancies. uPAR is not exclusive to senescent cells, and the 2020 work itself reported that uPAR-directed CAR T cells cause toxicity in mice at higher doses. Nobody has shown that this can be made safe enough to give to a healthy older person.

There is no human evidence of any kind for senolytic CAR T cells in ageing or senescence. A registry search returns no study of senolytic CAR T for an ageing or senescence indication; every registered study using the word senolytic is a small molecule or a supplement.

This matters more than usual here, because the gap between the biology and the clinic is not a funding gap that a trial would close. CAR T is a manufactured autologous cell product costing hundreds of thousands of dollars per patient, requiring chemotherapy conditioning and inpatient monitoring for cytokine release syndrome. Applying it to a person who is not ill, to clear cells whose removal has never been shown to help a person, is a risk-benefit calculation nobody has been able to make work on paper yet. The published route forward is to improve the specificity of the seno-antigen, not to take the current construct into people.

No senolytic of any kind has yet improved a clinical outcome in a randomised human trial. That sentence is the single most useful thing to carry into any senolytic discussion. Senescent cell burden has been reduced in people, by dasatinib plus quercetin, and the field has measured that reduction in skin and fat biopsies. What has not followed is a randomised trial in which people who got a senolytic ended up walking further, breaking fewer bones, or living longer than people who did not. The two randomised trials that tried, in pulmonary fibrosis and in postmenopausal bone turnover, did not separate from control.